SCHEMBL25819230

SCHEMBL25819230

O=C(OCc1ccccc1)N1CCN(c2ccc(-c3ccc(Br)nc3OCc3ccccc3)cc2F)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
NPSR1 Q6W5P4 2/20 0.45
GRM5 P41594 1/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
PTGDR2 Q9Y5Y4 8/20 0.43
CNR2 P34972 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
FFAR4 Q5NUL3 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
HDAC1 Q13547 1/20 0.39
HTT P42858 1/20 0.39
SLC6A9 P48067 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25822642 0.90 MAPT (0.46) MAPTNPSR1GRM5NPC1ALDH1A1
SCHEMBL25935052 0.90 MAPT (0.49) MAPTNPSR1GRM5NPC1ALDH1A1
SCHEMBL31333359 0.83 TMEM97 (0.43) MAPTNPSR1GRM5NPC1ALDH1A1
SCHEMBL25819309 0.82 MAPT (0.47) MAPTNPSR1ALDH1A1FFAR4KMT2A
SCHEMBL25819311 0.82 FFAR4 (0.47) GRM5FFAR4
SCHEMBL29013165 0.82 GRM5 (0.48) MAPTNPSR1GRM5NPC1ALDH1A1
SCHEMBL30643706 0.82 MAPT (0.45) MAPTNPSR1GRM5NPC1ALDH1A1
SCHEMBL26642195 0.81 TLR9 (0.46) MAPTNPSR1GRM5NPC1ALDH1A1
SCHEMBL30965745 0.80 TRPC3 (0.42) NPC1PTGDR2CNR2FFAR4
SCHEMBL29013207 0.79 PTGDR2 (0.42) NPSR1NPC1PTGDR2CNR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 MAPT 2055/4885NPSR1 4236/4885GRM5 3397/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 MAPT 1700/4885NPSR1 3663/4885GRM5 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.